Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCB052793 + itacitinib + azacitidine
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination regimen consisting of the investigational selective Janus kinase 1 (JAK1) inhibitor INCB052793, the selective JAK1 inhibitor itacitinib (also referred to as INCB039110), and the hypomethylating agent azacitidine. INCB052793 and itacitinib inhibit JAK1, reducing signaling in pathways involved in hematologic malignancy pathogenesis. Azacitidine is a nucleoside metabolic inhibitor that induces DNA hypomethylation and cytotoxicity, primarily used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)[2][4]. This combination has been studied in clinical trials for relapsed or refractory cases of AML and high-risk MDS, particularly those who have failed prior therapy with hypomethylating agents[2][1][4].
- Other names
- INCB052793 + itacitinib + azacitidine
02
Targets
DNMT (DNA methyltransferase)JAK1 (Janus kinase 1)
Beyond the preview
Go deeper on INCB052793 + itacitinib + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCB052793 + itacitinib + azacitidine.